share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A:其他
美股SEC公告 ·  08/23 16:57

Moomoo AI 已提取核心訊息

Cingulate Inc., a NASDAQ-listed biopharmaceutical company, announced the adjournment of its Special Meeting of Stockholders originally scheduled for August 23, 2024. The postponement was due to the lack of a quorum, as an insufficient number of shares were present or represented by proxy to conduct the meeting. The Board of Directors has reaffirmed its belief that the proposals outlined in the proxy statement are in the best interests of the stockholders. The adjourned meeting is now rescheduled for 11:00 a.m. Central Time on August 28, 2024, and will be accessible via a specified URL. Stockholders of record as of June 28, 2024, are encouraged to vote for all proposals ahead of the new meeting date by calling a toll-free number or voting online. Cingulate specializes in developing pharmaceutical products using its proprietary Precision Timed Release drug delivery platform, with a current focus on treating ADHD and exploring applications for anxiety disorders.
Cingulate Inc., a NASDAQ-listed biopharmaceutical company, announced the adjournment of its Special Meeting of Stockholders originally scheduled for August 23, 2024. The postponement was due to the lack of a quorum, as an insufficient number of shares were present or represented by proxy to conduct the meeting. The Board of Directors has reaffirmed its belief that the proposals outlined in the proxy statement are in the best interests of the stockholders. The adjourned meeting is now rescheduled for 11:00 a.m. Central Time on August 28, 2024, and will be accessible via a specified URL. Stockholders of record as of June 28, 2024, are encouraged to vote for all proposals ahead of the new meeting date by calling a toll-free number or voting online. Cingulate specializes in developing pharmaceutical products using its proprietary Precision Timed Release drug delivery platform, with a current focus on treating ADHD and exploring applications for anxiety disorders.
納斯達克上市公司Cingulate Inc.宣佈將原定於2024年8月23日舉行的特別股東大會延期。此次延期是因爲缺乏法定人數,由於股份的參加或代理人數不足,無法進行會議。董事會重申,代理聲明中概述的提案符合股東的最佳利益。已延期的會議現在重新安排在2024年8月28日中部時間上午11:00,並可通過指定的URL訪問。截至2024年6月28日作爲記錄日期的股東被鼓勵在新的會議日期之前通過免費電話或在線投票支持所有提案。Cingulate專注於利用其專有的精確定時釋放藥物輸送平台開發藥品,目前專注於治療注意力缺陷多動障礙並探索焦慮症的應用。
納斯達克上市公司Cingulate Inc.宣佈將原定於2024年8月23日舉行的特別股東大會延期。此次延期是因爲缺乏法定人數,由於股份的參加或代理人數不足,無法進行會議。董事會重申,代理聲明中概述的提案符合股東的最佳利益。已延期的會議現在重新安排在2024年8月28日中部時間上午11:00,並可通過指定的URL訪問。截至2024年6月28日作爲記錄日期的股東被鼓勵在新的會議日期之前通過免費電話或在線投票支持所有提案。Cingulate專注於利用其專有的精確定時釋放藥物輸送平台開發藥品,目前專注於治療注意力缺陷多動障礙並探索焦慮症的應用。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息